Showing 4741-4750 of 6411 results for "".
- EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in Chronic Hand Eczemahttps://practicaldermatology.com/news/ema-accepts-leo-pharmas-maa-for-delgocitinib-cream-in-chronic-hand-eczema/2461942/The European Medicines Agency (EMA) has validated LEO Pharma’s marketing authorization application for delgocitinib cream, an investigational product and topical pan-Janus kinase (JAK) inhibitor for the treatment of adult patients with moderate to severe chronic hand eczema (CHE).
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscree
- Immunotherapy Drug Combo Helps Extend Progression-Free Survival in Metastatic Melanomahttps://practicaldermatology.com/news/immunotherapy-drug-combo-helps-extend-progression-free-survival-in-metastatic-melanoma/2461940/Combining two immune checkpoint inhibitors helps overcome resistance to prior PD-1 therapy in patients with metastatic melanoma, a new study shows. The combination of ipilimumab and nivolumab showed a longer progression-free survival, but also a greater overall response rate t
- Inmagene's OX40 mAb Enters POC Study in ADhttps://practicaldermatology.com/news/inmagenes-ox40-mab-enters-poc-study-in-ad/2461934/The first patient has been dosed in a global multicenter proof-of-concept (POC) study of Inmagene Biopharmaceuticals’ IMG-007 in adults with moderate-to-severe atopic dermatitis (AD). The objective of the study is to assess the safety, pharmacokinetics, and efficacy of
- Verrica's Injectable Oncolytic Peptide Clears BCC in Early Phase 2 Datahttps://practicaldermatology.com/news/verricas-injectable-oncolytic-peptide-clears-bcc-in-early-phase-2-data/2461925/Verrica Pharmaceuticals Inc.’s VP-315 can clear basal cell carcinoma (BCC), according to data from Part 1 of an ongoing Phase 2 study presented at the 2023 American Academy of Dermatology Innovation Academy in Tampa, Fla. Given via injection into the tumor, VP-315 is an oncolytic
- DermaSensor Device Can Help Detect Skin Cancer Across Skin Toneshttps://practicaldermatology.com/news/dermasensor-device-can-help-detect-skin-cancer-across-skin-tones/2461924/DermaSensor's handheld Elastic Scattering Spectroscopy (ESS) device can help detect skin cancer in patients across different Fitzpatrick skin types, according to new research presented at the 2023 American Academy of Dermatology (AAD) Innovation Academy meeting. DermaSensor is desig
- The Dermatology Practice of the Future: AI-Powered Piction Health Dermatology Launches in Massachusettshttps://practicaldermatology.com/news/the-dermatology-practice-of-the-future-ai-powered-piction-health-dermatology-launches-in-mass/2461923/Piction Health Dermatology, an AI-enabled dermatology virtual clinic, is now open for Massachusetts residents. Piction's virtual clinic merges artificial intelligence (AI) with the expertise of board-certified dermatologists. Patients complete a short medical in
- PSA: Vets Warn That Minoxidil May Be Deadly to Petshttps://practicaldermatology.com/news/vets-warn-that-minoxidil-may-be-deadly-to-pets/2461917/Products like Rogaine, which contain minoxidil, can be very dangerous to animals, warn toxicology experts at Pet Poison Helpline. “Cats are particularly sensitive to this medication, and any exposure can result in severe poisoning and potentially death,” says Renee
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either
- Vacation Tanning Linked to Acute Changes in Skin Microbiomehttps://practicaldermatology.com/news/vacation-tanning-linked-to-acute-changes-in-skin-microbiome/2461912/Sun-seeking behaviors while on vacation may affect the skin’s microbiome, new research suggests. Prior to vacations to sunny destinations, which lasted at least seven days, the researchers analyzed participants’ skin. On day one, 28, and 84 post-holiday, participants’